Addex Therapeutics Ltd.
Clinical-stage biopharma developing allosteric modulators for neurological disorders.
ADXN | SW
Overview
Corporate Details
- ISIN(s):
- CH0029850754 (+2 more)
- LEI:
- 89450068Y9KVP2MQGH86
- Country:
- Switzerland
- Address:
- c/o Addex Pharma SA, Chemin des Aulx 12, 1228 Plan-Les-Ouates
- Sector:
- Manufacturing
Description
Addex Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, orally available small molecule drugs. The company specializes in an emerging class of therapeutics known as allosteric modulators. Its development pipeline targets neurological disorders and other central nervous system (CNS) diseases with significant unmet medical needs, leveraging its proprietary drug discovery platform.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-04-29 02:00 |
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
|
English | 8.6 KB | ||
| 2024-04-19 02:00 |
Addex to Present at the Swiss Biotech Day 2024
|
English | 5.3 KB | ||
| 2024-04-18 02:00 |
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corpor…
|
English | 11.9 KB | ||
| 2024-04-11 02:00 |
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Confere…
|
English | 6.1 KB | ||
| 2024-04-03 02:00 |
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Developm…
|
English | 11.2 KB | ||
| 2024-03-14 01:00 |
Addex to Present at the Bio-Europe Spring 2024 Conference
|
English | 5.8 KB | ||
| 2024-01-31 01:00 |
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & C…
|
English | 7.2 KB | ||
| 2024-01-09 01:00 |
Addex to Present at the Swiss Equities Baader Conference
|
English | 5.6 KB | ||
| 2024-01-05 01:00 |
Addex to Present at Biotech Showcase™ 2024
|
English | 6.1 KB | ||
| 2023-12-20 01:00 |
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
|
English | 5.4 KB | ||
| 2023-12-14 01:00 |
Addex Creates Treasury Shares
|
English | 5.8 KB | ||
| 2023-11-29 01:00 |
Addex Reports Q3 2023 Financial Results and Provides Corporate Update
|
English | 14.0 KB | ||
| 2023-11-28 01:00 |
Addex Convenes Extraordinary General Meeting
|
English | 5.4 KB | ||
| 2023-11-23 01:00 |
Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Con…
|
English | 6.3 KB | ||
| 2023-11-14 01:00 |
Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
|
English | 8.9 KB |
Automate Your Workflow. Get a real-time feed of all Addex Therapeutics Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Addex Therapeutics Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Addex Therapeutics Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-27 | N/A | Executive member | Buy | None | 301,345.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 53,760.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 45,450.00 CHF |
| 2023-11-27 | N/A | Non-Executive member | Buy | None | 44,856.00 CHF |
| 2023-11-27 | N/A | Non-Executive member | Buy | None | 24,423.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 5,487.00 CHF |
| 2023-11-27 | N/A | Non-Executive member | Buy | None | 3,927.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 2,150.00 CHF |
Peer Companies
